The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

For example, if a patient relapses after receiving three different treatments, their life expectancy will reduce to less than 10 months. 3 For the 24,000 people living with multiple myeloma in the ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Receiving the once-weekly KRd56 treatment ...

Multiple Myeloma ... Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

U.S. life expectancy saw a slight increase in 2022 — the latest data available — following a concerning two-year decline, according to the Centers for Disease Control and Prevention.

One morning in late April, a small brick health clinic along the Thurgood Marshall Highway bustled with patients. There was ...

In a new study, they showed that ... Higher Vitamin K Intake Linked to Lower Bone Fracture Risk Late in Life Nov. 28, 2022 — Research has revealed vitamin K1 can help reduce the risk of ...

Nov. 6, 2024 — Children whose mothers took extra vitamin D during pregnancy continue to have stronger bones at age seven, according to ... Two Key Genes Identified Linking Rheumatoid Arthritis ...